Select ongoing and pending clinical trials that allow prior treatment with a PD-1 or PD-L1 inhibitor identifierExperimental agentsRegimen targetsPhaseTumor type
NCT02899078Nivolumab + IbrutinibPD-1 + BTK1b/2RCC
NCT02923531Nivolumab + X4P-001PD-1 + CXCR41b/2aRCC
NCT02963610*Pembrolizumab + LenalidomidePD-1 + immunomodulatory1/2NSCLC
NCT03083808Pembrolizumab + Docetaxel/Pemetrexed/GemcitabinePD-1 + Chemotherapy2NSCLC
NCT03041181Nivolumab + DocetaxelPD-1 + Chemotherapy2NSCLC
NCT02437136Pembrolizumab + EntinostatPD-1 + HDAC1b/2NSCLC and melanoma
NCT02959437Pembrolizumab + Azacitidine + EpacadostatPD-1 + Chemotherapy + IDO-11/2NSCLC**
NCT03084640Pembrolizumab + CMP-001PD-1 + TLR91b/2melanoma

PD-1 programmed cell death protein 1, BTK: Bruton’s tyrosine kinase, RCC: renal cell carcinoma, CXCR4: C-X-C chemokine receptor type 4, NSCLC: non-small cell lung cancer, HDAC: histone deacetylases, IDO-1: Indoleamine 2,3-Dioxygenase 1, TLR9: Toll-like receptor 9, PD-L1 programmed death-ligand 1

*Prior treatment with anti-PD-1/PD-L1 is only allowed for the Phase 2 portion of this trial (which is only for NSCLC patients)

**Only the NSCLC cohort allows prior treatment with PD-1/PD-L1

Please note that this table was constructed using the following search terms on on 5/12/2017: “Nivolumab AND previously treated”, “Pembrolizumab AND previously treated”, and “Atezolizumab AND previously treated”. After generating a list of trials, the eligibility criteria for each trial was manually screened for inclusion in this table